Previous 10 | Next 10 |
Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“M...
Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced, Highly Qualified Board and Urges Shareholders to Reject Rubric...
Rubric Capital Management has boosted the number of nominees it is backing for Mereo BioPharma ( NASDAQ: MREO ) to five . The fifth nominee is Rubric founder David Rosen. In a letter to shareholders, Rosen wrote that "the problems on the Board of Mereo ( MREO )...
Director Nominees Possess the Financial, Regulatory and Strategic Expertise to Maximize Value for All Shareholders Details Mereo’s Desperate Efforts to Thwart Requisition of General Meeting of Shareholders Rubric Capital Management LP (“Rubric...
Rubric Capital Management rejected an offer from Mereo BioPharma Group ( NASDAQ: MREO ) to put a Rubric principal and another director on the company's board. Mereo ( MREO ) also said its offer included having two of its current board member retire. The biotech...
Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements of the Companies Act 2006 Which Apply to All U.K. Companies and Shareholders LONDON, Sept. 26,...
Summary This is an update on the previously written report on Mereo BioPharma Group, a London-based clinical-stage biopharma. Frustrated with the lack of engagement from the management, the activist filled a request for a special shareholder meeting aiming to replace 4 incumbent d...
Rubric Capital Management submitted a revised requisition to Mereo BioPharma's ( NASDAQ: MREO ) board for a general meeting of shareholders. Rubric — which claims to own ~14% stake in Mereo — issued an open letter on Sept. 14 criticizing th...
Submits Revised Requisition for General Meeting of Shareholders Condemns Company’s Governance and Corrects the Record on Mereo’s Misleading Public Statements Rubric Capital Management LP (“Rubric”), an investment advisor whose fund...
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination of etigilimab and nivolumab, including in PD-L1 negative or low subjects LONDON and ...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...